SEARCH

SEARCH BY CITATION

References

  • Bach J, Larimore B, Chinniah S, Connell-Crowley L. 2012. Understanding XMuLV clearance on protein A chromatography. 243 ACS Natl Meet Expo Abstr BIOT 405.
  • Bolton G, Cabatingan M, Rubino M, Lute S, Brorson K, Bailey M. 2005. Normal-flow virus filtration: Detection and assessment of the endpoint in bio-processing. Biotechnol Appl Biochem 42(Pt 2):133142.
  • Brorson K, de Wit C, Hamilton E, Mustafa M, Swann PG, Kiss R, Taticek R, Polastri G, Stein KE, Xu Y. 2002. Impact of cell culture process changes on endogenous retrovirus expression. Biotechnol Bioeng 80(3):257267.
  • Brorson K, Brown J, Hamilton E, Stein KE. 2003a. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chromatogr A 989(1):155163.
  • Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. 2003b. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82(3):321329.
  • CMC Biotech Working Group. 2009. A-Mab: A case study in bioprocess development: 1–278.
  • de Wit C, Fautz C, Xu Y. 2000. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 28(3):137148.
  • Fahrner RL, Whitney DH, Vanderlaan M, Blank GS. 1999. Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol Appl Biochem 30(Pt 2):121128.
  • Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, Blank GS. 2001. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 18:301327.
  • FDA. 2006a. Guidance for industry. Q8 (R2) pharmaceutical development.
  • FDA. 2006b. Guidance for industry. Q9 quality risk management.
  • Ghose S, Hubbard B, Cramer SM. 2007a. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol Bioeng 96(4):768779.
  • Ghose S, McNerney T, Hubbard B. 2007b. Protein A affinity chromatography for capture and purification of monoclonal antibodies and fc-fusion proteins: Practical considerations for process development. In: Shukla A, Etzel M, Gadam S, editors. Process scale bioseparations for the biopharmaceutical industry. New York: Taylor and Francis. p 463490.
  • Hahn R, Schlegel R, Jungbauer A. 2003. Comparison of protein A affinity sorbents. J Chromatogr B Analyt Technol Biomed Life Sci 790(1–2):3551.
  • Jungbauer A, Hahn R. 2004. Engineering protein A affinity chromatography. Curr Opin Drug Discov Devel 7(2):248256.
  • Liu HF, Ma J, Winter C, Bayer R. 2010. Recovery and purification process development for monoclonal antibody production. MAbs 2(5):480499.
  • Lute S, Norling L, Hanson M, Emery R, Stinson D, Padua K, Blank G, Chen Q, Brorson K. 2008. Robustness of virus removal by protein A chromatography is independent of media lifetime. J Chromatogr A 1205(1–2):1725.
  • Lute S, Wang H, Sanchez D, Barletta J, Chen Q, Brorson K. 2009. Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production. Biologicals 37(5):331337.
  • Miesegaes G, Bailey M, Willkommen H, Chen Q, Roush D, Blumel J, Brorson K. 2010a. Proceedings of the 2009 Viral Clearance Symposium, Indianapolis, IN, USA, 20–21 March 2009. 2009 Viral Clearance Symposium, Basel, Karger, International Association for Biologicals (IABS).
  • Miesegaes G, Lute S, Brorson K. 2010b. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 106(2):238246.
  • PDA. 2010. Technical report No. 47. Preparation of virus spike used for virus clearance studies. Preparation of virus spikes used for virus clearance studies task force. 165.
  • Rathore AS, Devine R. 2008. PDA workshop on “quality by design for biopharmaceuticals: Concepts and implementation,” May 21–22, 2007, Bethesda, Maryland. PDA J Pharm Sci Technol 62(5):380390.
  • Rathore AS, Mhatre R. 2009. Quality by design for biopharmaceuticals: Principles and case studies. Hoboken, NJ: Wiley.
  • Rathore AS, Winkle H. 2009. Quality by design for biopharmaceuticals. Nat Biotechnol 27(1):2634.
  • Rathore A. 2010. Implementation of quality by design (QbD) for biopharmaceutical products. PDA J Pharm Sci Technol 64(6):495496.
  • Shi L, Ho J, Norling LA, Roy M, Xu Y. 1999. A real time quantitative PCR-based method for the detection and quantification of simian virus 40. Biologicals 27(3):241252.
  • Shi L, Chen Q, Norling LA, Lau AS, Krejci S, Xu Y. 2004. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. Biotechnol Bioeng 87(7):884896.
  • Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies–application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848(1):2839.
  • Sisodiya VN, Lequieu J, Rodriguez M, McDonald P, Lazzareschi KP. 2012. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography. Biotechnol J 7(10):12331241.
  • Zhan D, Roy MR, Valera C, Cardenas J, Vennari JC, Chen JW, Liu S. 2002. Detection of minute virus of mice using real time quantitative PCR in assessment of virus clearance during the purification of Mammalian cell substrate derived biotherapeutics. Biologicals 30(4):259270.
  • Zhang M, Lute S, Norling L, Hong C, Safta A, O'Connor D, Bernstein LJ, Wang H, Blank G, Brorson K and others. 2009. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture protein A chromatography. Biotechnol Bioeng 102(5):14381447.